Clinical Trials
13 trialsNCT02445391 2026-05-12
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT02734290 2026-04-24
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Providence Health & Services
Phase 1/2 Active not recruiting
NCT03371017 2025-11-12
IMpassion132
Hoffmann-La Roche
Phase 3 Completed
NCT04849364 2025-05-31
PERSEVERE
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03487666 2024-12-03
OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
Georgetown University
Phase 2 Completed
NCT03872388 2024-10-02
Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03387085 2024-08-09
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
ImmunityBio, Inc.
Phase 1/2 Terminated
NCT03853707 2024-02-20
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT02000882 2022-02-07
STAR Cape+BKM120 MBC With Brain Met
US Oncology Research
Phase 2 Completed
NCT02555657 2021-12-10
KEYNOTE-119
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03044730 2020-07-13
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery
Northwestern University
Phase 2 Unknown
NCT01997333 2019-03-08
METRIC
Celldex Therapeutics
Phase 2 Completed
NCT01928680 2015-02-23
Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer
ChineseAMS
Phase 2 Unknown